97 related articles for article (PubMed ID: 27438978)
1. De novo everolimus for recipients of kidney transplants from HLA identical donors.
Cristelli MP; Ferreira A; Hannun P; Felipe C; Aguiar W; Franco M; Tedesco-Silva H; Medina-Pestana J
J Bras Nefrol; 2016 Jun; 38(2):225-33. PubMed ID: 27438978
[TBL] [Abstract][Full Text] [Related]
2. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation.
Yoshimura N; Nakao T; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Ushigome H
Transplant Proc; 2016 Apr; 48(3):786-9. PubMed ID: 27234736
[TBL] [Abstract][Full Text] [Related]
4. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
5. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
[TBL] [Abstract][Full Text] [Related]
6. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
8. Preventive effect of early introduction of everolimus and reduced-exposure tacrolimus on renal interstitial fibrosis in de novo living-donor renal transplant recipients.
Ishida H; Ogura G; Uehara S; Takiguchi S; Nakagawa Y; Hamano N; Koizumi M; Wada T; Fukagawa M; Nakamura M
Clin Exp Nephrol; 2020 Mar; 24(3):268-276. PubMed ID: 31792639
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
Hannun P; Felipe C; Ferreira A; Sandes-Freitas T; Cristelli M; Aguiar W; Franco M; Campos E; Gerbase de Lima M; Tedesco-Silva H; Medina-Pestana J
Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
[TBL] [Abstract][Full Text] [Related]
10. Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?
De Simone P; Saliba F; Dong G; Escrig C; Fischer L
Clin Transplant; 2016 Mar; 30(3):279-88. PubMed ID: 26717035
[TBL] [Abstract][Full Text] [Related]
11. Experience of Quatro-Therapy With Everolimus to Minimize Calcineurin Inhibitor for Kidney Transplant Recipients.
Nakamura N; Miyazaki T; Matsuzaki H; Furuya R; Miyajima S; Irie S; Matsuoka H; Tanaka M
Transplant Proc; 2017; 49(1):32-36. PubMed ID: 28104152
[TBL] [Abstract][Full Text] [Related]
12. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation.
Yamanaka K; Kakuta Y; Nakazawa S; Kato T; Abe T; Imamura R; Okumi M; Ichimaru N; Kyo M; Kyakuno M; Takahara S; Nonomura N
Transplant Proc; 2016 Apr; 48(3):781-5. PubMed ID: 27234735
[TBL] [Abstract][Full Text] [Related]
13. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
Belliere J; Kamar N; Mengelle C; Allal A; Sallusto F; Doumerc N; Game X; Congy-Jolivet N; Esposito L; Debiol B; Rostaing L
Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Results in Recipients of Late Conversion to a Calcineurin Inhibitor-Free Regimen with Everolimus After Kidney Transplantation.
Iwahara N; Hotta K; Hirose T; Shinohara N
Transplant Proc; 2023 May; 55(4):803-808. PubMed ID: 37147197
[TBL] [Abstract][Full Text] [Related]
15. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
Cruzado JM; Pascual J; Sánchez-Fructuoso A; Serón D; Díaz JM; Rengel M; Oppenheimer F; Hernández D; Paravisini A; Saval N; Morales JM;
Transpl Int; 2016 Dec; 29(12):1317-1328. PubMed ID: 27648523
[TBL] [Abstract][Full Text] [Related]
16. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
17. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
Hiramitsu T; Okada M; Futamura K; Yamamoto T; Tsujita M; Goto N; Narumi S; Watarai Y; Takeda A; Iwasaki K; Uchida K; Kobayashi T
Int Immunopharmacol; 2016 Oct; 39():192-198. PubMed ID: 27491025
[TBL] [Abstract][Full Text] [Related]
18. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
Trials; 2016 Feb; 17():92. PubMed ID: 26888217
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months).
Felipe C; Tedesco-Silva H; Ferreira Brigido A; Bessa A; Ruppel P; Hiramoto L; de Paula M; Cristelli M; Stopa S; Mansur J; Viana L; Fahham L; Pepe C; Medina-Pestana J
Value Health Reg Issues; 2017 Dec; 14():108-115. PubMed ID: 29254534
[TBL] [Abstract][Full Text] [Related]
20. Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.
Hauser IA; Marx S; Sommerer C; Suwelack B; Dragun D; Witzke O; Lehner F; Schiedel C; Porstner M; Thaiss F; Neudörfl C; Falk CS; Nashan B; Sester M
Eur J Immunol; 2021 Apr; 51(4):943-955. PubMed ID: 33306229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
